| abstract |
Nucleotide sequences coding for certain canine β-adrenergic receptors, particularly the β2- (SEQ ID NO 1) and β3- (SEQ ID NO 24) receptors, as well as the use of said sequences as probes, for expressing canine β-adrenergic receptors, for studying the tissue location of the expressed receptor (PCR, Northern blot), for carrying out directed mutagenesis, and for receptor structure-function studies, are disclosed. The use of said canine β-adrenergic receptors for preparing specific antibodies is also disclosed. Furthermore, a differential screening method for affinity studies of substances having an agonist or antagonist activity for canine β3-adrenergic receptors, and kits for studying the effectiveness of various substances for said canine β3-adrenergic receptors, are disclosed. Such substances are particularly useful for selectively treating obesity or other obesity-related metabolic disorders in dogs, as well as any other diseases in which canine β3 receptors are involved. |